METHOD FOR DETERMINING CLINICALLY SIGNIFICANT FATIGUE IN A PATIENT WITH RHEUMATOID ARTHRITIS AGAINST THE BACKGROUND OF 5-YEAR THERAPY WITH BASIC ANTI-INFLAMMATORY DRUGS OR BASIC ANTI-INFLAMMATORY DRUGS IN COMBINATION WITH GENETICALLY ENGINEERED BIOLOGICAL DRUGS AND/OR PSYCHOPHARMACOTHERAPY AND CONCOMITANT ANXIETY-DEPRESSIVE SPECTRUM DISORDER Russian patent published in 2021 - IPC A61B5/00 G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine, namely to rheumatology, and can be used to determine clinically significant fatigue in patients with rheumatoid arthritis (RA) with comorbid anxiety-depressive spectrum disorders (ADSD). In a patient with rheumatoid arthritis (RA) on the background of 5-year therapy with basic anti-inflammatory drugs (BAID) or basic anti-inflammatory drugs in combination with genetically engineered biological drugs (GEBD) and/or psychopharmacotherapy and concomitant disorder of the anxiety-depressive spectrum are determined: therapy of clinically significant fatigue according to the FSS scale; presence of minor depression after 5 years of RA therapy; having major depression after 5 years of RA therapy; the presence of a previous myocardial infarction (MI) before the start of therapy; the age of the patient with RA before the start of therapy, in years; severity of functional limitations after 5-year therapy for RA according to the HAQ index; serum C-reactive protein (CRP) level after 5 years of RA therapy; inflammatory activity of RA according to the DAS28 index after 5 years of RA therapy, in points. Based on the totality of the data obtained, clinically significant fatigue is determined according to the stated formula.

EFFECT: method provides for the determination of clinically significant fatigue in a patient with RA and concomitant ADSD against the background of 5-year therapy with AIDs or AIDs in combination with GEBD and/or psychopharmacotherapy by assessing the complex of the most significant indicators.

1 cl, 1 dwg, 9 tbl, 4 ex